首页|黄芪注射液辅助免疫化疗对子宫内膜癌患者免疫功能及血清肿瘤分子的影响

黄芪注射液辅助免疫化疗对子宫内膜癌患者免疫功能及血清肿瘤分子的影响

扫码查看
目的 探讨黄芪注射液辅助免疫化疗对子宫内膜癌患者免疫功能及血清肿瘤分子的影响.方法 选取2014年5月~2016年10月浙江省宁波大学医学院附属医院收治的112例子宫内膜癌患者,随机分为观察组(n=56)与对照组(n=56).对照组进行常规化疗,观察组在对照组基础上加用黄芪注射液.比较2组患者临床疗效,检测比较2组患者化疗前后免疫功能、血清肿瘤分子水平,统计2组患者不良反应发生率.结果 化疗后观察组的总缓解率73.22%,显著高于对照组的51.79%(P<0.01).与化疗前相比,化疗后2组患者外周血中CD4+、CD8+比例均降低,且观察组降低幅度小于对照组,对照组外周血中CD4+/CD8+明显降低,且低于观察组(P<0.01).化疗后2组患者血清IgG、IgA水平均无明显变化,但观察组高于对照组(P<0.05);与化疗前相比,化疗后观察组血清IgM、补体C3水平均升高,对照组血清IgM、补体C3水平均下降,且观察组高于对照组(P<0.05或P<0.01).化疗过程中,观察组胃肠道反应、粒细胞减少、血小板减少、肝肾功能损害发生率均低于对照组(P<0.05或P<0.01).结论 黄芪注射液辅助免疫化疗可提升子宫内膜癌患者化疗的临床疗效,有效降低血清肿瘤分子水平,避免化疗对机体免疫功能的损伤,减轻不良反应,安全性良好.
Effects of adjuvant immunochemotherapy with astragalus injection on the immunologic function and serum tumor molecule of endometrial cancer patients
Objective To explore the effects of adjuvant immunochemotherapy with astragalus injection on the immune function and serum tumor molecule of endometrial cancer patients. Methods 112 cases endometrial cancer patients were selected from May 2014 to October 2016 as the study object and divided into observation group (n=56) and control group (n=56) randomly. The control group was treated with regular chemotherapy, and the observation group was treated with astragalus injection on the basis of control group. Compared the clinical efficacy of 2 groups, deceted and compared the immune function and levels of serum tumor molecule before and after chemotherapy in 2 groups, statisticsed the incidence of toxicity in 2 groups. Results The remission rate of the observation group was 73.22%, which was significant higher than 51.79% of the control group after chemotherapy (P<0.01). Compared with before chemotherapy, the CD4+, CD8+ proportion in peripheral blood of 2 groups decreased, and the reduction extent of observation group was less than control group, the CD4+/CD8+ in peripheral blood of the control group decreased significantly, and which was lower than the observation group (P<0.01). The serum IgG, IgA of 2 groups had no obvious change, but observation group was higher than control group (P<0.05). Compared with before chemotherapy, the levels of serum IgM and complement C3 of the observation group increased, IgM and complement C3 of the control group decreased after chemotherapy, and the observation group was higher than the control group (P<0.05 or P<0.01). The Incidence of gastrointestinal reaction, granulocytopenia, thrombopenia, hepatic and renal dysfunction of the observation group was lower than those of the control group during chemotherapy (P<0.05 or P<0.01). Conclusion Adjuvant immunochemotherapy with astragalus injection can improve the clinical efficacy, reduce the levels of serum tumor molecular, avoid the damage of chemotherapy to the immune function of organism, reduce the toxicity, security is good.

endometrial canceradjuvant immunochemotherapyastragalus injectionimmune functionserum tumor molecule

杜军辉

展开 >

浙江省宁波大学医学院附属医院 妇产科,浙江 宁波 315020

子宫内膜癌 辅助免疫化疗 黄芪注射液 免疫功能 血清肿瘤分子

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(11)
  • 2
  • 7